A Study to Evaluate the Efficacy and Safety of AD-208

Addpharma

Status and phase: Completed; Phase 3

Conditions: Androgenetic Alopecia

Treatments: Drug: placebo of AD-208; Drug: AD-208; Drug: AD-2081; Drug: placebo of AD-2081

Study type: Interventional

Funder types: Industry

Identifiers

NCT04825561

AD-208P3

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of AD-208.

Full description

The purpose of this study is to evaluate the efficacy and safety of AD-208 in male patients with androgenetic alopecia.

Enrollment: 139 patients

Sex: Male

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male patients aged 18-50 years, inclusive
• Patients who meet the appropriate criteria according to the classification of hair loss
• Signed informed consent

Exclusion criteria

• Patients with hair loss disorders other than androgenetic alopecia
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

139 participants in 3 patient groups, including a placebo group

Active Comparator

Active Comparator group

Description:

AD-208 and Placebo of AD-2081

Treatment:

Drug: AD-208

Drug: placebo of AD-2081

Placebo Comparator

Placebo Comparator group

Description:

Placebo of AD-208 and Placebo of AD-2081

Treatment:

Drug: placebo of AD-208

Drug: placebo of AD-2081

Experimental Comparator

Experimental group

Description:

Placebo of AD-208 and AD-2081

Treatment:

Drug: placebo of AD-208

Drug: AD-2081